Holen Sie sich die Stockscreener-App
25.83
0.27%
0.07
Handel nachbörslich:
25.95
0.12
+0.46%
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Is IDEAYA Biosciences Inc.’s ROIC above industry averageJuly 2025 Recap & AI Based Buy and Sell Signals - khodrobank.com
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - Seeking Alpha
IDEAYA Biosciences Rings the Opening Bell - Nasdaq
IDEAYA Biosciences: Barclays initiates coverage at Overweight, PT $40. - AInvest
IDEAYA enrolls first lung cancer patient in targeted therapy trial - Investing.com
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - PR Newswire
IDEAYA Biosciences: A High-Conviction Biotech Play with Precision Oncology Catalysts - AInvest
Transcript : IDEAYA Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 09 - MarketScreener
Will IDEAYA Biosciences Inc. continue its uptrendJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - Newser
Is IDEAYA Biosciences Inc. stock risky to hold nowInsider Buying & Advanced Technical Analysis Signals - khodrobank.com
Is IDEAYA Biosciences Inc. gaining market shareWeekly Trend Summary & Stepwise Swing Trade Plans - khodrobank.com
How hedge fund analytics apply to IDEAYA Biosciences Inc. stockJuly 2025 Opening Moves & High Conviction Buy Zone Alerts - Newser
How to forecast IDEAYA Biosciences Inc. trends using time seriesJuly 2025 Levels & Weekly High Conviction Ideas - Newser
Trend analysis for IDEAYA Biosciences Inc. this weekMarket Rally & Daily Profit Maximizing Trade Tips - Newser
IDEAYA Biosciences submits IND for new cancer drug IDE892 - Investing.com
What high frequency data says about IDEAYA Biosciences Inc.Portfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Analyzing IDEAYA Biosciences Inc. with risk reward ratio chartsJuly 2025 Movers & AI Based Buy and Sell Signals - Newser
Risk adjusted return profile for IDEAYA Biosciences Inc. analyzedMarket Trend Report & Growth-Oriented Investment Plans - Newser
Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage - Stock Titan
How to escape a deep drawdown in IDEAYA Biosciences Inc.July 2025 Closing Moves & Weekly High Return Forecasts - Newser
Is IDEAYA Biosciences Inc. a cyclical or defensive stock2025 Valuation Update & Safe Entry Zone Tips - khodrobank.com
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionWeekly Profit Summary & Risk Managed Investment Entry Signals - Newser
Backtesting results for IDEAYA Biosciences Inc. trading strategiesTrade Signal Summary & High Win Rate Trade Tips - Newser
Comparing IDEAYA Biosciences Inc. in custom built stock radars2025 Institutional Moves & Short-Term Trading Alerts - Newser
Will IDEAYA Biosciences Inc. stock recover after recent drop2025 Analyst Calls & Reliable Trade Execution Plans - Newser
Best data tools to analyze IDEAYA Biosciences Inc. stockEarnings Overview Summary & Low Volatility Stock Suggestions - Newser
How to monitor IDEAYA Biosciences Inc. with trend dashboardsJuly 2025 Update & Weekly Stock Breakout Alerts - Newser
Regression analysis insights on IDEAYA Biosciences Inc. performance2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
In Brief: Servier, IDEAYA Partner On Darovasertib For Uveal Melanoma - insights.citeline.com
Volatility clustering patterns for IDEAYA Biosciences Inc.2025 Fundamental Recap & AI Powered Trade Plan Recommendations - Newser
How to recover losses in IDEAYA Biosciences Inc. stockMarket Growth Review & Weekly Watchlist for Hot Stocks - Newser
Will IDEAYA Biosciences Inc. benefit from geopolitical trendsRate Cut & Weekly Consistent Profit Watchlists - khodrobank.com
Servier pays big for ex-US darovasertib rights - The Pharma Letter
How high can IDEAYA Biosciences Inc. stock go2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Can IDEAYA Biosciences Inc. rally from current levelsStop Loss & Fast Momentum Entry Tips - Newser
Ideaya Biosciences Shares Jump Following $210 Million Licensing Deal with Servier - MSN
The Oncology Institute, Inc. shares fall 1.18% intraday as IDEAYA Biosciences announces positive trial data for darovasertib and crizotinib combination. - AInvest
IDEAYA Biosciences and Servier in-pact to develop eye cancer treatment - Seeking Alpha
Ideaya Biosciences stock surges after $210 million licensing deal with Servier - Investing.com
Precision Biosciences shares fall 1.22% premarket after IDEAYA Biosciences' partnership with Servier. - AInvest
Is this a good reentry point in IDEAYA Biosciences Inc.Inflation Watch & Weekly Top Stock Performers List - Newser
IDEAYA Biosciences' Strategic Licensing of Darovasertib: A Catalyst for Sustainable Growth and Value Creation - AInvest
IDEAYA Biosciences, Inc. Enters into License Agreement with Les Laboratoires Servier - MarketScreener
Analyzing drawdowns of IDEAYA Biosciences Inc. with statistical tools2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
IDEAYA Biosciences Soars 10.63% on Servier Partnership for Uveal Melanoma Treatment - AInvest
IDEAYA Biosciences Licenses Darovasertib to Servier - TipRanks
Real time breakdown of IDEAYA Biosciences Inc. stock performance2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
IDEAYA Biosciences receives $210mln upfront for darovasertib license, up to $320mln in milestones. - AInvest
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - PR Newswire
What data driven models say about IDEAYA Biosciences Inc.’s future2025 AllTime Highs & Verified Momentum Stock Alerts - Newser
Is It Too Late to Sell IDEAYA Biosciences Inc. getLinesFromResByArray error: size == 0 - kangso.co.kr
Is IDEAYA Biosciences Inc. a momentum stock2025 Price Momentum & AI Powered Market Trend Analysis - khodrobank.com
Can IDEAYA Biosciences Inc. expand into new marketsWeekly Trade Report & Weekly Stock Performance Updates - khodrobank.com
IDEAYA Biosciences Inc. Reversal Rally May Surprise Bears getLinesFromResByArray error: size == 0 - thegnnews.com
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):